Rajeev Chauhan, MD
Nephrology · Columbus, GANPI 1104812437
Payments from drug & device makers
Across 418 payments — averaging $2651.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$395K
- Astrazeneca UK Limited$379K
- Boehringer Ingelheim International GmbH$172K
- Alnylam Pharmaceuticals Inc.$118K
- AstraZeneca$13K
- Akebia Therapeutics Inc$13K
- plus $19K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 4 | $395,139 |
| Astrazeneca UK Limited | 11 | $378,528 |
| Boehringer Ingelheim International GmbH | 18 | $172,124 |
| Alnylam Pharmaceuticals Inc. | 53 | $117,558 |
| AstraZeneca(2 entities) | 51 | $13,090 |
| Akebia Therapeutics Inc | 23 | $13,006 |
| Vifor Pharma, Inc. | 15 | $7,414 |
| Otsuka America Pharmaceutical, Inc. | 20 | $6,453 |
| Vantive US Healthcare LLC | 10 | $962 |
| Amgen(2 entities) | 24 | $734 |
| OPKO Pharmaceuticals, LLC | 70 | $614 |
| Mallinckrodt Hospital Products Inc. | 18 | $511 |
| Baxter Healthcare | 7 | $368 |
| Bayer | 12 | $342 |
| Novo Nordisk | 13 | $234 |
| GSK | 8 | $200 |
| Novartis | 9 | $186 |
| Inari Medical, Inc. | 4 | $161 |
| Travere Therapeutics, Inc. | 18 | $140 |
| Ardelyx, Inc. | 7 | $137 |
| Johnson & Johnson | 1 | $104 |
| Kyowa Kirin, Inc. | 4 | $78 |
| Calliditas Therapeutics US Inc. | 4 | $71 |
| Cormedix Inc. | 2 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Fresenius USA Manufacturing, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
How this compares
$1,108,474 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Columbus
- Tamorie SmithColumbus$1.9M
- Rajendran AlappanColumbus$346K
- Arachelvi DhandayuthapaniColumbus$110K
- Fahd SyedColumbus$48K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.